• Sign up to our Free Newsletter
  • Contact Us
  • Editorial Submission
Microbiome Times Magazine
  • Human Health
  • Finance
  • Drug Database
    • Login
    • About
  • Issue Archive
  • Advertise
  • Recruitment Marketing

Pharma & Human Health

Finance

BioGaia AB – Interim management statement 1 January – 31 March 2018

April 25, 2018 Microbiome Times

Comments from the Managing Director: “Sales for the first quarter of 2018 amounted to SEK 157 million, which was an increase of 13% (excluding foreign exchange effects) compared to the corresponding period last year. Revenue […]

Pharma & Human Health

Drinking Affects Mouth Bacteria Linked to Diseases

April 24, 2018 Microbiome Times

When compared with nondrinkers, men and women who had one or more alcoholic drinks per day had an overabundance of oral bacteria linked to gum disease, some cancers, and heart disease. By contrast, drinkers had […]

Pharma & Human Health

Synthetic Biologics Provides Update on Development of SYN-004 (ribaxamase), for the Prevention of C. difficile Infection

April 23, 2018 Microbiome Times

Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, today announced that it has preliminary agreement from the U.S. […]

Pharma & Human Health

AOBiome Therapeutics Expands Clinical-Stage Pipeline, Initiates Phase 2 Clinical Trial for Episodic Migraine

April 23, 2018 Microbiome Times

AOBiome Therapeutics (“AOBiome”), a clinical-stage life sciences company advancing patented microbiome-based therapies, today announced that AOBiome has expanded its clinical-stage pipeline with the initiation of a randomized, double-blind, Phase 2 study to assess safety, tolerability, […]

Pharma & Human Health

Prota Therapeutics Partners With World Leading Bioscience Company, Chr. Hansen

April 20, 2018 Microbiome Times

Allergy immunotherapy company Prota Therapeutics Pty Ltd (Prota), is pleased to announce it has partnered with Chr. Hansen, a leading global bioscience company, to manufacture and supply pharmaceutical quality LGG®1 probiotic strain, Lactobacillus rhamnosus, initially […]

Pharma & Human Health

Dannon® Awards $50,000 in Student Grants to Further Yogurt and Gut Microbiome Exploration

April 18, 2018 Microbiome Times

For the seventh year in a row, Dannon®, as a part of Danone North America, has demonstrated their commitment to science and education through the Dannon® Gut Microbiome, Yogurt and Probiotics Fellowship Grant Program. This […]

Pharma & Human Health

Optibiotix Health plc Signs 5 year Exclusive Agreement with Trigen Pharma

April 18, 2018 Microbiome Times

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces it has entered into a five year distribution agreement with Trigen Pharma International (Pvt) […]

Pharma & Human Health

Landmark Study To Address Global Malnutrition And Restorative Effect Of Infant Probiotic

April 17, 2018 Microbiome Times

Evolve BioSystems, Inc. and the icddr,b (International Centre for Diarrhoeal Disease Research, Bangladesh) today announced their collaboration, funded by the Bill & Melinda Gates Foundation, to study the use of Evivo® in infants to aid […]

Finance

WACKER Strengthens Its Pharmaceutical-Protein Business and Buys SynCo Bio Partners

April 17, 2018 Microbiome Times

Wacker Chemie AG has acquired a Dutch site for manufacturing biopharmaceuticals, live microbial products and vaccines, plus the associated business, from SynCo Bio Luxembourg S.à.r.l.. The Munich-based chemical company announced the acquisition today. For WACKER, […]

Pharma & Human Health

MicroBiome Therapeutics Launches Clinically-Tested Dietary Supplement Engineered to Modulate the Gut Microbiome

April 11, 2018 Microbiome Times

NEW ORLEANS, April 11, 2018 /PRNewswire/ — MicroBiome Therapeutics, LLC (MBT), a leading company applying the science of the gastrointestinal (GI) microbiome to promote health and wellness, today announced the launch of BiomeBliss™, a patented, […]

Pharma & Human Health

Second Genome Presents Clinical and Preclinical Data Supporting Development of Its P2X7 Inhibitor, SGM-1019, in NASH at the EASL International Liver Congress 2018

April 9, 2018 Microbiome Times

Second Genome, Inc., a leader in the development of novel medicines derived from the human microbiome, today announced the presentation of preclinical data and results from a Phase 1 study in healthy volunteers with its […]

Posts navigation

« 1 … 82 83 84 85 »

Sign Up to Free Newsletter

NEW WHITEPAPER: ORAL DELIVERY OF LIVE BIOTHERAPEUTIC PRODUCTS:

Editor’s Choice

  • Siolta Therapeutics Reports Positive Phase 2 Results from the ADORED Study
    November 17, 2025
  • The OMNIgene™•VAGINAL device – Optimized solutions for vaginal microbiome studies
    November 12, 2025
  • MRM Health Raises €55 Million Series B to Advance Microbiome-Based Biotherapeutic Product Pipeline
    September 4, 2025
  • Targeting the ileo-colonic region: Innovative solutions for sensitive APIs
    August 21, 2025
  • EXPERT’Biome CDMO by Lallemand at Microbiome Times Forum
    June 23, 2025
sign up

Sign up to the Microbiome Times newsletter